体部动力学可能优于：连续 ctDNA 预测早期治疗反应。
Truncal Dynamics May Trump: Serial ctDNA to Predict Early Therapeutic Response.
机构信息
Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
出版信息
Clin Cancer Res. 2023 Jan 17;29(2):302-304. doi: 10.1158/1078-0432.CCR-22-2793.
Abstract
Promising utility of using serial ctDNA in metastatic colorectal cancer to both refine patient selection, reduce toxicity due to chemotherapy, and to evaluate emerging resistance mechanisms may lead the way to novel therapeutic strategies. However, important questions remain in validating its use as a predictive biomarker of treatment response. See related article by Vidal et al., p. 379.
摘要
在转移性结直肠癌中使用连续 ctDNA 来改善患者选择、减少化疗毒性以及评估新出现的耐药机制具有很大的应用潜力，可能为新的治疗策略铺平道路。然而，在验证其作为治疗反应预测生物标志物的用途方面仍存在一些重要问题。详见 Vidal 等人的相关文章，第 379 页。
相似文献
1
Truncal Dynamics May Trump: Serial ctDNA to Predict Early Therapeutic Response.体部动力学可能优于：连续 ctDNA 预测早期治疗反应。
Clin Cancer Res. 2023 Jan 17;29(2):302-304. doi: 10.1158/1078-0432.CCR-22-2793.
2
Dynamic changes in longitudinal circulating tumour DNA profile during metastatic colorectal cancer treatment.转移性结直肠癌治疗过程中纵向循环肿瘤 DNA 谱的动态变化。
Br J Cancer. 2022 Sep;127(5):898-907. doi: 10.1038/s41416-022-01837-z. Epub 2022 May 28.
3
Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer.循环肿瘤 DNA 指导转移性结直肠癌的治疗。
Clin Cancer Res. 2023 Nov 14;29(22):4530-4539. doi: 10.1158/1078-0432.CCR-23-0079.
4
Circulating tumor DNA is a sensitive marker for routine monitoring of treatment response in advanced colorectal cancer.循环肿瘤 DNA 是一种敏感的标志物，可用于常规监测晚期结直肠癌的治疗反应。
Carcinogenesis. 2020 Nov 13;41(11):1507-1517. doi: 10.1093/carcin/bgaa102.
5
Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis.循环肿瘤 DNA 作为可切除和不可切除 IV 期结直肠癌的生物标志物：系统评价和荟萃分析。
Eur J Cancer. 2021 Feb;144:368-381. doi: 10.1016/j.ejca.2020.11.025. Epub 2021 Jan 7.
6
Evolving Role of Circulating Tumor DNA and Emerging Targeted Therapy in Colorectal Cancer.循环肿瘤 DNA 的不断演变的角色和新兴的靶向治疗在结直肠癌中的应用。
Hematol Oncol Clin North Am. 2022 Jun;36(3):583-601. doi: 10.1016/j.hoc.2022.02.009. Epub 2022 May 13.
7
Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis.循环肿瘤 DNA 分析揭示转移性结直肠癌化疗进展后的突变进化。
Int J Cancer. 2023 Aug 1;153(3):571-583. doi: 10.1002/ijc.34558. Epub 2023 May 16.
8
Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics.从结直肠癌患者的血液衍生循环肿瘤 DNA 进行基因组分析：对靶向治疗的反应和耐药性的影响。
Mol Cancer Ther. 2019 Oct;18(10):1852-1862. doi: 10.1158/1535-7163.MCT-18-0965. Epub 2019 Jul 18.
9
RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.RAS/BRAF 循环肿瘤 DNA 突变作为预测转移性结直肠癌患者一线化疗反应的标志物。
Can J Gastroenterol Hepatol. 2018 Mar 7;2018:4248971. doi: 10.1155/2018/4248971. eCollection 2018.
10
Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.动态监测循环肿瘤 DNA 预测结直肠肝转移切除术后辅助化疗的预后和疗效。
Theranostics. 2021 May 12;11(14):7018-7028. doi: 10.7150/thno.59644. eCollection 2021.
引用本文的文献
1
Circulating tumor DNA mutation analysis: advances in its application for early diagnosis of hepatocellular carcinoma and therapeutic efficacy monitoring.循环肿瘤 DNA 突变分析：在肝细胞癌早期诊断和疗效监测中的应用进展。
Aging (Albany NY). 2024 Jul 19;16(14):11460-11474. doi: 10.18632/aging.205980.
本文引用的文献
1
Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study.液体活检可早期检测到分子应答，并预测转移性结直肠癌患者接受一线化疗联合西妥昔单抗治疗的获益：PLATFORM-B 研究。
Clin Cancer Res. 2023 Jan 17;29(2):379-388. doi: 10.1158/1078-0432.CCR-22-1696.
2
Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance).在晚期结直肠癌的一线化疗中使用西妥昔单抗获得的基因组改变：CALGB/SWOG-80405 试验（Alliance）的循环肿瘤 DNA 分析。
J Clin Oncol. 2023 Jan 20;41(3):472-478. doi: 10.1200/JCO.22.00365. Epub 2022 Sep 6.
3
Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices.利用循环肿瘤 DNA 进行结直肠癌诊疗：现状与未来发展。
J Clin Oncol. 2022 Aug 20;40(24):2846-2857. doi: 10.1200/JCO.21.02615. Epub 2022 Jul 15.
4
Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer.转移部位对转移性结直肠癌患者循环肿瘤DNA的影响。
JCO Precis Oncol. 2022 Apr;6:e2100535. doi: 10.1200/PO.21.00535.
5
Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer.结直肠癌患者游离 DNA 的基因组特征
Cancer Discov. 2018 Feb;8(2):164-173. doi: 10.1158/2159-8290.CD-17-1009. Epub 2017 Dec 1.
6
Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.循环肿瘤DNA作为转移性结直肠癌患者治疗反应的早期标志物。
Ann Oncol. 2015 Aug;26(8):1715-22. doi: 10.1093/annonc/mdv177. Epub 2015 Apr 7.
7
Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy.采用微滴式数字 PCR 检测晚期结直肠癌患者中 KRAS 突变亚克隆对接受抗 EGFR 治疗的临床意义。
Clin Cancer Res. 2015 Mar 1;21(5):1087-97. doi: 10.1158/1078-0432.CCR-14-0983. Epub 2014 Sep 23.
8
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.结直肠癌中针对 EGFR 阻断的获得性耐药的分子进化。
Nature. 2012 Jun 28;486(7404):537-40. doi: 10.1038/nature11219.
9
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.结直肠癌中 KRAS 突变的出现和抗 EGFR 治疗的获得性耐药。
Nature. 2012 Jun 28;486(7404):532-6. doi: 10.1038/nature11156.
Zotero 插件